ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy

Abstract

BackgroundGraft local infusion and splenectomy in ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) are associated with high rates of operative complications. MethodsConsecutive ABO-I LDLT patients treated at the National Cancer Centre between January 2012 and February 2013 were identified. The protocol for ABO-I LDLT at the study centre included the administration of rituximab (300mg/m2) at 2 weeks preoperatively, followed by plasma exchanges (target isoagglutinin titre: ≤1:8), basiliximab (20mg on the day of surgery and on postoperative day 4), and i.v. immunoglobulin (0.8g/kg on postoperative days 1 and 4) without graft local infusion or splenectomy. ResultsFifteen patients (11 men and four women) who underwent transplantation for liver cirrhosis (n = 3) or hepatocellular carcinoma (n = 12) were identified. These included 13 patients with hepatitis B virus infection, one with hepatitis C virus infection and one with alcoholic cirrhosis. The mean age, mean Model for End-stage Liver Disease (MELD) score and mean graft-to-recipient weight ratio (GRWR) of these patients was 51.8 years, 11.5 and 0.84, respectively. The median isoagglutinin titre before plasma exchange was 1:32 (range: 1:4 to 1:256). There were no hyperacute or antibody-mediated rejections. No bacterial or fungal infections were observed. Complications included herpes zoster viral infection in one patient, postoperative bleeding in one patient and extrahepatic biliary stricture in three patients. ConclusionsThis simplified ABO-I LDLT protocol showed good graft outcomes without immunologic failure or serious infections.